The U.S. Food and Drug Administration today announced that it is updating the warning labels required on three gadolinium-based MRI contrast agents sold in the U.S. due to the risk of nephrogenic systemic fibrosis.
FDA updates warning labels on gadolinium contrast
Sep 8, 2010
Latest in MRI
U.S. FDA clears software update for Hyperfine's Optive AI
December 15, 2025
Adding AI to MRI improves return to play classification frameworks
December 10, 2025
Long COVID's neurological effects persist
December 9, 2025



.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=100&q=70&w=100)

.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=167&q=70&w=250)











